FDA Action Alert: Nabriva, Seattle Genetics, Sarepta and Nektar

FDA Action Alert: Nabriva, Seattle Genetics, Sarepta and Nektar

Asco 2019 event analyser – low-key meeting belies some huge stock moves

Asco 2019 event analyser – low-key meeting belies some huge stock moves

All the ASCO skinny: Lynparza’s pancreatic win, Amgen’s KRAS spotlight, Merck’s history-busting and more

All the ASCO skinny: Lynparza's pancreatic win, Amgen's KRAS spotlight, Merck's history-busting and more

ASCO GU Preview: Merck, Bristol-Myers Squibb, Pfizer and More

ASCO GU Preview: Merck, Bristol-Myers Squibb, Pfizer and More

The 20 Hottest Pipeline Drugs to Watch in 2019

The 20 Hottest Pipeline Drugs to Watch in 2019

Biopharma in 2019

Biopharma in 2019

Looking into the Crystal Ball: Top Predictions for 2019 by Biopharma Execs

Looking into the Crystal Ball: Top Predictions for 2019 by Biopharma Execs

Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Bristol-Myers Squibb Reports 11% Increase in Total Revenues for Q2

  Bristol-Myers Squibb reported a strong second quarter, with total revenues of $5.7 billion, up 11 percent from the same quarter in 2017, when it reported $5.144 billion. Sales were driven by Eliquis (apixaban) and Opdivo (nivolumab). Eliquis global sales grew 40 percent by $474 million. Opdivo grew 36 percent by $432 million. Orencia grew by 9 … Συνεχίστε να διαβάζετε Bristol-Myers Squibb Reports 11% Increase in Total Revenues for Q2.